Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) formats, becoming the country’s only company to offer the drug in all three biotechnology dosage forms: vials, pre-filled syringes, and pre-filled pens.
Semaglutide, a GLP-1 receptor agonist, is widely used for the management of Type 2 diabetes and is increasingly recognized for its role in weight and metabolic management.
The principal activity of the company is to manufacture and market pharmaceutical products.
About the Author
Written by the expert legal team at Javid Law Associates. Our team specializes in corporate law, tax compliance, and business registration services across Pakistan.
Verified Professional
25+ Years Experience